• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why AMC Entertainment Shares Are Trading Lower By Around 13%? Here Are 59 Stocks Moving In Thursday's Mid-Day Session

    12/22/22 1:13:48 PM ET
    $ACMR
    $AEHR
    $ALVO
    $AMC
    Industrial Machinery/Components
    Technology
    Electrical Products
    Industrials
    Get the next $ACMR alert in real time by email

    Gainers

    • Core Scientific, Inc. (NASDAQ:CORZ) shares jumped 188% to $0.1471. Core Scientific shares dipped 75% on Wednesday after the company filed for Chapter 11 bankruptcy.
    • IsoPlexis Corporation (NASDAQ:ISO) rose 82.4% to $1.2598. Berkeley Lights announced plans to acquire IsoPlexis in all-stock transaction at $57.8 million.
    • AMC Entertainment Holdings, Inc. (NYSE:APE) gained 77% to $1.21. AMC Entertainment Holdings Inc (NYSE:AMC) announced an equity capital raise and a debt for equity exchange. The company also proposed a vote to convert AMC Preferred Equity Units into common shares and enact a reverse stock split.
    • ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) climbed 69% to $5.05 after the company announced it has entered into a clinical development collaboration for a potential Phase 2 study of ORIC-533 in multiple myeloma with Pfizer and agreed to sell about 5.38 million of its common shares at a price of $4.65 per share to Pfizer for proceeds of approximately $25 million.
    • ProQR Therapeutics N.V. (NASDAQ:PRQR) shares jumped 61% to $2.6400 after the company, along with Eli Lilly, announced the expansion of their licensing and collaboration agreement of new genetic medicines. ProQR will receive an upfront payment of $75 million, plus an equity investment.
    • E-Home Household Service Holdings Limited (NASDAQ:EJH) gained 27.8% to $0.90.
    • Scopus BioPharma Inc. (NASDAQ:SCPS) climbed 25% to $0.10.
    • Alvotech (NASDAQ:ALVO) gained 25.8% to $10.44 after the company issued an update on U.S. regulatory status of AVT02, the company’s proposed high-concentration, interchangeable biosimilar to Humira.
    • Rekor Systems, Inc. (NASDAQ:REKR) gained 23.3% to $1.1482.
    • Edesa Biotech, Inc. (NASDAQ:EDSA) jumped 20.4% to $1.65. Edesa Biotech recently received Fast Track designation from the FDA for its monoclonal antibody candidate, EB05.
    • Polished.com Inc. (NYSE:POL) surged 19.3% to $0.68 after the company announced internal investigation results, corporate updates and the board of directors' remedial actions.
    • China Index Holdings Limited (NASDAQ:CIH) jumped 17.5% to $0.8930. China Index Holdings entered into definitive agreement for going-private transaction.
    • Optical Cable Corporation (NASDAQ:OCC) jumped 16.3% to $4.1527 after the company reported Q4 sales results were higher year over year.
    • Oragenics, Inc. (NYSE:OGEN) jumped 15.5% to $0.1524 after the company reported toxicology results for its COVID-19 intranasal vaccine candidate.
    • United Insurance Holdings Corp. (NASDAQ:UIHC) surged 15.5% to $0.8356.
    • PLx Pharma Inc. (NASDAQ:PLXP) rose 14.9% to $0.1851.
    • Baudax Bio, Inc. (NASDAQ:BXRX) gained 14.6% to $2.59.
    • WeTrade Group, Inc. (NASDAQ:WETG) rose 13.4% to $0.2750 after dropping 37% on Wednesday.
    • Grom Social Enterprises, Inc. (NASDAQ:GROM) rose 12.5% to $1.70 after jumping 28% on Wednesday.
    • Visionary Education Technology Holdings Group Inc. (NASDAQ:VEDU) gained 10.7% to $0.6149.
    • Gogoro Inc. (NASDAQ:GGR) gained 10.4% to $3.72.
    • Connexa Sports Technologies Inc. (NASDAQ:CNXA) gained 10.4% to $0.2296.
    • MillerKnoll, Inc. (NASDAQ:MLKN) surged 9.5% to $20.00 after the company reported better-than-expected Q2 EPS and sales results.
    • Cleveland-Cliffs Inc. (NYSE:CLF) gained 8.8% to $16.48 after the company said it expects to achieve higher fixed prices for steel in 2023.


    Losers

    • Ever-Glory International Group, Inc. (NYSE:EVK) shares dipped 35.5% to $0.3489. Ever-Glory announced voluntary delisting from the Nasdaq Global Market.
    • Immuron Limited (NASDAQ:IMRN) declined 34.4% to $1.41.
    • ECARX Holdings Inc. (NASDAQ:ECX) dropped 28.3% to $8.45.
    • Caravelle International Group (NASDAQ:CACO) fell 22.6% to $1.3466.
    • Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) fell 22.5% to $17.26 after the company issued an update on anticipated registration path for RP-A501 in danon disease following end-of-Phase 1 FDA meeting.
    • Evolv Technologies Holdings, Inc. (NASDAQ:EVLV) dropped 22.3% to $2.13. Evolv Technology announced $75 million in non-dilutive debt financing with Silicon Valley Bank.
    • Camber Energy, Inc. (NYSE:CEI) shares tumbled 21.7% to $3.0627. Camber Energy recently announced a one-for-fifty reverse-stock-split.
    • Sintx Technologies, Inc.(NASDAQ:SINT) dropped 18.9% to $9.52. SINTX Technologies recently announced it has received a Phase I contract for $150,000 from the U.S. Missile Defense Agency.
    • Amprius Technologies, Inc. (NYSE:AMPX) dipped 18.7% to to $7.26.
    • Lannett Company, Inc. (NYSE:LCI) fell 18.6% to $0.7001.
    • Cenntro Electric Group Limited (NASDAQ:CENN) fell 18.3% to $0.3303. Cenntro Electric shares jumped 52% on Wednesday after the company announced it has begun shipments of LS260 and LS100 vans to European markets.
    • Sunlight Financial Holdings Inc. (NYSE:SUNL) dropped 18.2% to $1.4150.
    • Heliogen, Inc. (NYSE:HLGN) fell 18% to $0.4934.
    • Gorilla Technology Group Inc. (NASDAQ:GRRR) dropped 17.8% to $4.10.
    • Electrameccanica Vehicles Corp. (NASDAQ:SOLO) fell 17.4% to $0.6722.
    • Westrock Coffee Company, LLC (NASDAQ:WEST) fell 17.2% to $11.05 after gaining 10% on Wednesday.
    • Oxbridge Re Holdings Limited (NASDAQ:OXBR) dropped 17.1% to $1.21.
    • 180 Life Sciences Corp. (NASDAQ:ATNF) fell 16.6% to $1.76. 180 Life Sciences recently announced a $6 million registered direct offering.
    • Powerbridge Technologies Co., Ltd. (NASDAQ:PBTS) fell 16.3% to $11.05 after jumping 29% on Wednesday. Powerbridge Technologies recently announced the strategic acquisition of DTI Group.
    • Mobile Global Esports Inc. (NASDAQ:MGAM) fell 14.8% to $0.78 after jumping 45% on Wednesday. Mobile Global Esports recently announced a share repurchase program up to $1 million.
    • Lanvin Group Holdings Limited (NYSE:LANV) dropped 14.7% to $4.6894.
    • Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) dropped 13.5% to $3.45.
    • Cassava Sciences, Inc. (NASDAQ:SAVA) fell 13.4% to $31.97. Cassava Sciences recently announced it completed dosing in an open-label study of Simufilam for Alzheimer's disease.
    • Lightwave Logic, Inc. (NASDAQ:LWLG) dropped 12.8% to $4.71.
    • AMC Entertainment Holdings, Inc. (NYSE:AMC) fell 12.7% to $4.62 after the company announced a $110 million equity capital raise. The company also announced a proposed vote to convert its preferred equity units into common shares and implement a reverse stock split.
    • DatChat, Inc. (NASDAQ:DATS) fell 12.5% to $0.3457 after gaining 12% on Wednesday.
    • Aehr Test Systems (NASDAQ:AEHR) dropped 11.6% to $20.16.
    • ACM Research, Inc. (NASDAQ:ACMR) fell 10.9% to $7.58.
    • Carvana Co. (NYSE:CVNA) fell 10.3% to $3.8750.
    • Wayfair Inc. (NYSE:W) dipped 9.7% to $33.21.
    • Venus Concept Inc. (NASDAQ:VERO) fell 8% to $0.2743. Venus Concept shares jumped 18% on Wednesday after the company received an FDA 510(k) clearance to market its AI.ME next-generation robotic technology for fractional skin resurfacing.
    • ContextLogic Inc. (NASDAQ:WISH) dropped 8% to $0.4759.
    • Avaya Holdings Corp. (NYSE:AVYA) fell 7.4% to $0.2077 in pre-market trading after jumping around 8% on Wednesday.
    • Helius Medical Technologies, Inc. (NASDAQ:HSDT) shares fell 7.3% to $0.2288. Maxim Group recently initiated coverage on the stock with a Buy rating and a $1 price target.
    • Micron Technology, Inc. (NASDAQ:MU) fell 3.4% to $ 49.46 after the company reported downbeat results for its first quarter and issued weak earnings forecast for the second quarter. The company also announced plans to lay off 10% of its workforce next year.

    Also Check This Out Kellogg, United Natural Foods And 2 Other Stocks Insiders Are Selling

    Get the next $ACMR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACMR
    $AEHR
    $ALVO
    $AMC

    CompanyDatePrice TargetRatingAnalyst
    Cleveland-Cliffs Inc.
    $CLF
    3/25/2026Sector Weight
    KeyBanc Capital Markets
    Micron Technology Inc.
    $MU
    3/19/2026Buy → Hold
    Summit Insights
    Micron Technology Inc.
    $MU
    3/19/2026$450.00 → $500.00Buy
    Needham
    ProQR Therapeutics N.V.
    $PRQR
    3/12/2026$9.00Outperform
    Oppenheimer
    Core Scientific Inc.
    $CORZ
    3/3/2026$23.00Hold → Buy
    Needham
    Aehr Test Systems
    $AEHR
    3/2/2026Mkt Perform → Outperform
    William Blair
    Wayfair Inc.
    $W
    2/20/2026$114.00 → $105.00Overweight
    Analyst
    Micron Technology Inc.
    $MU
    2/17/2026$380.00 → $450.00Buy
    Needham
    More analyst ratings

    $ACMR
    $AEHR
    $ALVO
    $AMC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Nijhawan Pardeep bought $6,599 worth of shares (1,000 units at $6.60), increasing direct ownership by 0.16% to 628,813 units (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    3/10/26 5:02:16 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Weiss Eric Stanton bought $101,700 worth of shares (7,000 units at $14.53), increasing direct ownership by 3% to 252,262 units (SEC Form 4)

    4 - Core Scientific, Inc./tx (0001839341) (Issuer)

    3/10/26 4:08:53 PM ET
    $CORZ
    Finance: Consumer Services
    Finance

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $ACMR
    $AEHR
    $ALVO
    $AMC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-2) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    10/21/24 10:44:05 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-1) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    10/21/24 2:59:28 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-3) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    10/21/24 2:59:28 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACMR
    $AEHR
    $ALVO
    $AMC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by Nygaard James P Jr

    4/A - Core Scientific, Inc./tx (0001839341) (Issuer)

    3/27/26 6:45:21 PM ET
    $CORZ
    Finance: Consumer Services
    Finance

    SEC Form 4 filed by Ew Healthcare Partners, L.P.

    4 - Venus Concept Inc. (0001409269) (Issuer)

    3/27/26 4:05:02 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Conine Steven

    4 - Wayfair Inc. (0001616707) (Issuer)

    3/26/26 5:10:00 PM ET
    $W
    Catalog/Specialty Distribution
    Consumer Discretionary

    $ACMR
    $AEHR
    $ALVO
    $AMC
    SEC Filings

    View All

    SEC Form 8-K filed by Rekor Systems Inc.

    8-K - Rekor Systems, Inc. (0001697851) (Filer)

    3/27/26 4:15:05 PM ET
    $REKR
    Telecommunications Equipment
    Telecommunications

    Amendment: SEC Form SCHEDULE 13G/A filed by Wayfair Inc.

    SCHEDULE 13G/A - Wayfair Inc. (0001616707) (Subject)

    3/27/26 2:17:33 PM ET
    $W
    Catalog/Specialty Distribution
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Rocket Pharmaceuticals Inc.

    SCHEDULE 13G/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

    3/27/26 12:59:30 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACMR
    $AEHR
    $ALVO
    $AMC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC

    SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that it will report combination dose optimization data from the Phase 1b trial of rinzimetostat (ORIC-944) in patients with metastatic castration resistant prostate cancer (mCRPC) in a conference call and webcast on Tuesday, March 31, 2026 at 4:30pm ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call.

    3/27/26 8:30:00 AM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

    First FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2 Severe LAD-I is an ultra-rare, life-threatening pediatric genetic immunodeficiency characterized by recurrent infections and high early-childhood mortality without treatment FDA grants Rare Pediatric Disease Priority Review Voucher Company to host conference call today, March 27 at 8:30 AM ET Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRESLADI™ (marnet

    3/27/26 7:00:00 AM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment

    TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today provided an update on preparations and reaffirmed enrollment timeline guidance for its Phase 2 clinical study of EB06 in moderate-to-severe nonsegmental vitiligo. The announcement coincides with the company's sponsorship and participation today at the Global Vitiligo Foundation (GVF) Annual Scientific Symposium in Denver, Colorado. Edesa reported that it has selected JSS Medical Research, Inc. to act as its clinical research organization (CRO) for the proof-of-concept study, and ou

    3/26/26 9:15:00 AM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACMR
    $AEHR
    $ALVO
    $AMC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    KeyBanc Capital Markets resumed coverage on Cleveland-Cliffs

    KeyBanc Capital Markets resumed coverage of Cleveland-Cliffs with a rating of Sector Weight

    3/25/26 8:29:13 AM ET
    $CLF
    Metal Mining
    Basic Materials

    Micron downgraded by Summit Insights

    Summit Insights downgraded Micron from Buy to Hold

    3/19/26 8:25:02 AM ET
    $MU
    Semiconductors
    Technology

    Needham reiterated coverage on Micron with a new price target

    Needham reiterated coverage of Micron with a rating of Buy and set a new price target of $500.00 from $450.00 previously

    3/19/26 7:49:58 AM ET
    $MU
    Semiconductors
    Technology

    $ACMR
    $AEHR
    $ALVO
    $AMC
    Leadership Updates

    Live Leadership Updates

    View All

    SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

    Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026 SALT LAKE CITY, Utah, March 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today provided a corporate business update highlighting recent clinical, operational, and leadership milestones that the Company believes position it for commercial expansion and future revenue growth. The update follows a series of key developments, including the successful completion of the first human surgical procedure us

    3/23/26 9:15:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    Cleveland-Cliffs Inc. Appoints Ralph Michael as Lead Director

    Cleveland-Cliffs Inc. (NYSE:CLF) today announced the appointment of Ralph "Mike" Michael III as Lead Independent Director of the Company's Board of Directors, effective immediately. Mr. Michael succeeds Douglas Taylor as Lead Independent Director, following the Board's acceptance of Mr. Taylor's resignation due to a change in his professional circumstances. Under the Company's Corporate Governance Guidelines, Mr. Taylor submitted a mandatory resignation following his acceptance of a new professional role. Lourenco Goncalves, Cliffs' Chairman, President and Chief Executive Officer, said: "I thank Douglas Taylor, the former CEO of Casablanca Capital at the time of the Company's hostile take

    2/23/26 6:01:00 PM ET
    $CLF
    Metal Mining
    Basic Materials

    $ACMR
    $AEHR
    $ALVO
    $AMC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Rocket Pharmaceuticals Inc.

    SC 13D/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

    12/16/24 7:51:51 PM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Carvana Co.

    SC 13D/A - CARVANA CO. (0001690820) (Subject)

    12/16/24 6:13:26 PM ET
    $CVNA
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Evolv Technologies Holdings Inc.

    SC 13G/A - Evolv Technologies Holdings, Inc. (0001805385) (Subject)

    12/12/24 3:21:41 PM ET
    $EVLV
    Computer peripheral equipment
    Technology

    $ACMR
    $AEHR
    $ALVO
    $AMC
    Financials

    Live finance-specific insights

    View All

    ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC

    SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that it will report combination dose optimization data from the Phase 1b trial of rinzimetostat (ORIC-944) in patients with metastatic castration resistant prostate cancer (mCRPC) in a conference call and webcast on Tuesday, March 31, 2026 at 4:30pm ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call.

    3/27/26 8:30:00 AM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

    First FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2 Severe LAD-I is an ultra-rare, life-threatening pediatric genetic immunodeficiency characterized by recurrent infections and high early-childhood mortality without treatment FDA grants Rare Pediatric Disease Priority Review Voucher Company to host conference call today, March 27 at 8:30 AM ET Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRESLADI™ (marnet

    3/27/26 7:00:00 AM ET
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MillerKnoll, Inc. Reports Third Quarter Fiscal 2026 Results

    ZEELAND, Mich., March 25, 2026 /PRNewswire/ -- MillerKnoll Inc. (NASDAQ:MLKN), a growth-oriented small-cap value company in the industrial and consumer sectors, today reported results for the third quarter fiscal 2026 ended February 28, 2026. Visit the Company's investor relations website to view the earnings release. At 5:00 p.m. Eastern Time today, MillerKnoll will hold a conference call and webcast to discuss third quarter results.  Participants may access the conference call live via webcast on the Company's investor relations website.  Alternatively, participants may access

    3/25/26 4:05:00 PM ET
    $MLKN
    Office Equipment/Supplies/Services
    Consumer Discretionary